The company reiterated its FY25 GAAP net loss guidance of between $1.03B-$1.09B, which includes estimated non-cash stock-based compensation expense of between $115M-$130M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines reports Q3 EPS ($1.61), consensus ($1.41)
- Boeing upgraded, Charter downgraded: Wall Street’s top analyst calls
- Revolution Medicines initiated with an Outperform at RBC Capital
- Revolution Medicines: Promising Oncology Leader with Strategic Advancements and Competitive Edge
- Revolution Medicines Advances RAS(ON) Inhibitor Study in Gastrointestinal Cancers